Kyowa Hakko Kirin Co., Limited

Masayo Suzuki

Hiroshi Ando

Akiko Furuya

Tsuguo Kubota

Norihiko Shiraishi

Hiroe Toki

Takeshi Takahashi

Kazuyasu Nakamura

Yutaka Kanda

Yoshinori Yamashita

So Ohta

Shinji Nara

Takamasa Sugita

Hisashi Tagaya

Mariko Nakano

Keiko Kawashima

Hiromi Ando

Shinobu Kawamoto

Tomoyuki Nakazato

Hiroaki Nakamura

An object of the present invention is to provide a monoclonal antibody which is useful for treating or diagnosing a disease relating to system ASC amino acid transporter 2 (hereinafter, referred to as 'ASCT2') or a method using the antibody. The present invention provides a monoclonal antibody which specifically recognizes a native three-dimensional structure of an extracellular region of ASCT2 and binds to the extracellular region, or an antibody fragment thereof; a hybridoma which produces the antibody; a DNA which encodes the antibody; a vector which contains the DNA; a transformant obtainable by introducing the vector; a process for producing an antibody or an antibody fragment thereof using the hybridoma or the transformant; and a therapeutic agent using the antibody or the antibody fragment thereof, and a diagnostic agent using the antibody or the antibody fragment thereof.

DNA encoding an anti-system ASC amino acid transporter 2 (ASCT2) antibody

Anti-system ASC amino acid transporter 2 (ASCT2) antibody

An object of the present invention is to provide a monoclonal antibody which is useful as a diagnostic agent or a therapeutic agent for a disease relating to a polypeptide encoded by Claudin-4 (hereinafter referred to as 'CLDN4') gene or a polypeptide encoded by a Claudin-3 (hereinafter referred to as 'CLDN3') gene, or a method for using the same. Accordingly, the present invention provides a monoclonal antibody or an antibody fragment thereof, which specifically recognizes three-dimensional structure of an extracellular region of CLDN4 and binds to the extracellular region; a monoclonal antibody or an antibody fragment thereof, which specifically recognizes three-dimensional structure of both of extracellular regions of CLDN3 and CLDN4 and binds to the extracellular regions; a hybridoma which produces the antibody; a DNA which encodes the antibody; a vector which comprises the DNA; a transformant obtained by transforming the vector; a process for producing an antibody or an antibody fragment thereof using the hybridoma or the transformant; and a diagnostic agent or a therapeutic agent for a disease relating to a polypeptide encoded by CLDN4 gene and/or CLDN3 gene using the antibody or the antibody fragment.

Anti-claudin-4 antibody

The present invention provides a type I insulin-like growth factor receptor (IGF-1R) inhibitor comprising, as an active ingredient, an indazole derivative represented by Formula (I): {wherein Rrepresents &#x2014;NRR[wherein Rrepresents a hydrogen atom or the like, Rrepresents substituted or unsubstituted lower alkyl, &#x2014;C(&#x2550;O)R(wherein Rrepresents substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl or the like), or the like], or the like, and Rand Rmay be the same or different and each represents a hydrogen atom, hydroxy, substituted or unsubstituted lower alkoxy, or the like} or a pharmaceutically acceptable salt thereof, and the like.

IGF-1R inhibitor

Growing community of inventors

Tokyo, Japan

Masayo Suzuki